| Document |
Document Title |
|
WO/2007/057407A2 |
The invention relates to insecticidal methods using 3-amino-1,2-benzoisothiazole compounds of the formula (I) wherein the variables n and R1 to R6 are as defined in the description. The invention relates to methods of combating or contro...
|
|
WO/2007/053135A1 |
The present application discloses methods of detecting and treating cancer which express MUC1 aberrantly.
|
|
WO/2007/047737A1 |
Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or con...
|
|
WO/2007/039176A1 |
The invention relates to derivatives of 2-aminothiazoles and 2-aminooxazoles in all its stereoisomeric forms, enantiomeric forms and mixtures in any ratio, and its physiologically acceptable salts and tautomeric forms showing PPARdelta a...
|
|
WO/2007/031745A1 |
A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.
|
|
WO/2007/028163A1 |
This invention relates to new fluorescent chemical entities that are designed to attach to biocompatible molecules to form in vivo optical imaging agents.
|
|
WO/2007/028037A1 |
This invention relates to new fluorescent chemical entities, especially fluorescent molecules that comprise biocompatible N, N-disubstituted sulfonamide fluorochromes. This invention also relates to the corresponding reactive versions of...
|
|
WO2005117882A9 |
The present invention provides compounds of Formula (I ) or (II), salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds...
|
|
WO/2006/125370A1 |
The present invention discloses a kind of aromatic ether compounds of general formula (I), in which the definitions of substituents are illuminated as description. The aromatic ether compounds of the present invention have broad spectrum...
|
|
WO/2006/128120A2 |
The invention provides lapachone analogs and derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can a...
|
|
WO/2006/125972A1 |
Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes....
|
|
WO/2006/122661A1 |
The present invention relates to compounds of the Formula (I), in which R1; R2; R3; V; G1 and G2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a ...
|
|
WO/2006/114400A1 |
This invention relates to novel oxadiazole derivatives of formula (I) which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the tr...
|
|
WO/2006/108107A1 |
Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, an...
|
|
WO/2006/093911A2 |
Compounds of Formula: (I) are provided, as are methods for their preparation. The variables in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are pa...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO/2006/077217A1 |
The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or -COO-C1-C4-alkyl group; Y represents NH, N-C1-C10-alkyl, O, or S; X represents O, S, NH, N-C...
|
|
WO/2006/074884A1 |
The present invention is concerned with novel thiazole 4-carboxyamide derivatives of the general formula (I) and with methods for the preparation thereof, which compounds are useful as metabotropic glutamate receptor antagonists: wherein...
|
|
WO/2006/074940A2 |
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...
|
|
WO/2006/056875A1 |
The present invention relates to a new class of oxazolidinone derivatives, to their use as antibacterial agents, to pharmaceutical compositions containing these compounds and to methods for their preparation.
|
|
WO/2006/036670A1 |
Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.
|
|
WO/2006/032173A1 |
This invention relates to aryl hydrazide compounds of formula I, their geometric isomers, medical salts or hydrates, their preparation process and medical compositions containing the compounds. The invention also relates to usage of the ...
|
|
WO/2006/026033A2 |
Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided ...
|
|
WO/2006/021448A1 |
The present invention describes novel anti-bacterial compounds of formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase.
|
|
WO/2006/014394A1 |
The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators.
|
|
WO/2005/111029A1 |
The invention relates to novel substituted thiophene-2-carboxamides of general formula (I), in which A, and R1 to R8c are defined as cited in claim 1. The invention also relates to the tautomers, enantiomers, diastereomers, mixtures and ...
|
|
WO/2005/097136A1 |
Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one o...
|
|
WO/2005/095440A1 |
The present invention relates to compounds of the Formula (I), in which R°; R1; R2; R3; R4; R5; R6; Q; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds....
|
|
WO/2005/087751A2 |
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and condit...
|
|
WO/2005/082897A1 |
The present invention relates to novel amidoxime and amidine oxazolidinones of formula I , wherein R2, Y1, Y 2, Y3, X, W, G and U are as defined herein in the specification. The compounds of the present invention have potent activities a...
|
|
WO/2005/080344A1 |
The present invention relates to agricultural insecticide and germicide and discloses substituted azole compounds, its preparation and application. The substituted azole compounds of the present invention is represented as formula (I). T...
|
|
WO/2005/079802A1 |
The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to ps...
|
|
WO/2005/068459A1 |
The invention relates to optical data carriers containing a preferably transparent substrate that is optionally already coated with at least one reflective layer. An information layer on which data can be written with light, optionally a...
|
|
WO/2005/058884A2 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane c...
|
|
WO/2005/058842A1 |
The invention relates to the compounds of formula (I), in which R1, R2, R3, R4, Q and Z are as defined in the specification. The invention also relates to the pharmaceutical compositions containing these compounds. The invention generall...
|
|
WO/2005/037830A1 |
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor.
|
|
WO/2005/002577A1 |
The use of compounds of the general formula wherein the substituents are as described in claim 1 or pharmaceutically active acid-addition salts thereof for the preparation of medicaments for the treatment of schizophrenia.
|
|
WO/2004/101557A1 |
The invention concerns blood clotting. The invention particularly concerns certain heterocyclic compounds, methods for the production thereof, their use for treating and/or preventing diseases, and their use for producing medicaments for...
|
|
WO/2004/092123A2 |
This invention relates to various anti-fungall agents including agents that are inhibitors of fungal invasion.
|
|
WO/2004/092134A1 |
This invention relates to a compound which is [c]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating disease...
|
|
WO/2004/089937A1 |
A compound of the general formula: (I) or its salt or a solvate thereof; and a drug comprising the same, e.g., a preventive and/or therapeutic agent for ischemic diseases or platelet aggregation inhibitor comprising the compound, salt or...
|
|
WO/2004/084813A2 |
The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivative...
|
|
WO/2004/076412A2 |
Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors...
|
|
WO/2004/065380A1 |
The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of...
|
|
WO/2004/062590A2 |
The use of bicyclic carbohydrates for the treatment of parasite infections is described. Different bicyclic carbohydrates have been tested in vitro against a number of protozoa. These compounds also have been screened against viruses, tu...
|
|
WO/2004/026863A1 |
Novel thiazole derivatives of formula I a - c, intermediates fo their preparation, pharmaceutical compositions containing them and their medicinal use are described. The compounds of the present invention are potent inhibitors of transfo...
|
|
WO/2004/026292A1 |
Antitussives containing as the active ingredient compounds represented by the general formula (I) or salts thereof: (I) (wherein A is alkoxycarbonylalkyl or the like and R is optionally protected hydroxyl, or A and R may be united to for...
|
|
WO/2004/009092A1 |
The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formula...
|
|
WO/2003/097605A1 |
The invention relates to a 3-pyridylcarboxamide derivative of formula (I), wherein the various symbols are as defined in the description, compositions thereof, their use for the control of pests, and to processes for their preparation.
|
|
WO/2003/078438A1 |
Compounds useful for inhibiting HIV protease are disclosed. Methods of making the compounds, and their use as thereapeutic agents, for example, in treating wild-type HIV and of multidrug-resistant strains of HIV, also are disclosed.
|
